Document:

EX-10.9

 Exhibit 10.9 

SECOND AMENDMENT 
 This
Second Amendment pertains to the License Agreement (hereinafter the “License Agreement”) effective August 11, 1997, by and between the MASSACHUSETTS INSTITUTE OF TECHNOLOGY (hereinafter M.I.T.) and ADVANCED INHALATION RESEARCH, INC.
(hereinafter AIR). 
 WHEREAS, AIR intends to enter into an agreement with a CORPORATE PARTNER (as defined in the License Agreement)
according to which AIR will be receiving MILESTONE PAYMENTS (as defined in the License Agreement); and 
 WHEREAS, in the License Agreement
the MILESTONE PAYMENTS are subject to royalties according to paragraphs 4.1(h), (i), and (j); 
 WHEREAS, in the agreement with the
CORPORATE PARTNER, the MILESTONE PAYMENTS are fully creditable against earned royalties on NET SALES which the CORPORATE PARTNER will be paying AIR when product is on the market, such credits scheduled so that the payments normally due to AIR on NET
SALES can be reduced by up to fifty percent in a given year until the full credit is used up; and 
 WHEREAS, the CORPORATE PARTNER wishes
assurance that should the License Agreement terminate M.I.T. will grant to the CORPORATE PARTNER rights to practice under the PATENT RIGHTS under reasonable terms; 

NOW THEREFORE, the parties hereby agree to modify the License Agreement by: 

A) adding the following sentence to the end of paragraph 4.1(h): 

To the extent such MILESTONE PAYMENTS are creditable against royalties on NET SALES normally due LICENSEE from a CORPORATE PARTNER, M.I.T.
agrees that the royalties on MILESTONE PAYMENTS normally due M.I.T. under this paragraph 4.1(h) are also creditable against RUNNING ROYALTIES due M.I.T. on NET SALES according to paragraph 4.1(d), provided, however, that the royalties due M.I.T.
under paragraph 4.1(d) are reduced by no more than half in a single calendar year. 
 B) adding the following sentence to the end of
paragraph 4.1(i): 
 To the extent such MILESTONE PAYMENTS are creditable against royalties on NET SALES normally due LICENSEE from a
CORPORATE PARTNER, M.I.T. agrees that the royalties on MILESTONE PAYMENTS normally due M.I.T. under this paragraph 4.1(i) are also creditable against RUNNING ROYALTIES due M.I.T. on NET SALES according to paragraphs 4.1(e), provided, however, that
the royalties due M.I.T. under paragraph 4.1 (e) are reduced by no more than half in a single calendar year. 
 C) adding the following
sentence to the end of paragraph 4.1(j): 
 To the extent that MILESTONE PAYMENTS are creditable against royalties on NET SALES normally due
LICENSEE from a CORPORATE PARTNER, M.I.T. agrees that the royalties on MILESTONE PAYMENTS normally due M.I.T. under this paragraph 4.1(j) are also creditable against RUNNING ROYALTIES due M.I.T. on NET SALES according to paragraphs 4.1(f), provided,
however, that the royalties due M.I.T. under paragraph 4.1(f) are reduced by no more than half in a single calendar year. 
  

									
	MASSACHUSETTS INSTITUTE OF TECHNOLOGY	 		 	ADVANCED INHALATION RESEARCH, INC.
					
	By:	 	 /s/ Lori Pressman
	 		 	By:	 	 /s/ David Edwards

	Name:	 	 Lori Pressman
	 		 	Name:	 	 David Edwards

	Title:	 	 Assistant Director, Technology Licensing Office
	 		 	Title:	 	 President

	Date:	 	 July 17, 1998
	 		 	Date:	 	 7/20/98EX-10.10

 Exhibit 10.10 

THIS EXHIBIT HAS BEEN REDACTED AND IS THE SUBJECT OF A CONFIDENTIAL TREATMENT REQUEST. REDACTED MATERIAL IS MARKED WITH [* * *] AND HAS
BEEN FILED SEPARATELY WITH THE SECURITIES AND EXCHANGE COMMISSION. 
 THIRD AMENDMENT 

This Third Amendment pertains to the License Agreement (hereinafter the “License Agreement”) effective August 11, 1997 by and between the
MASSACHUSETTS INSTITUTE OF TECHNOLOGY (hereinafter M.I.T.) and ADVANCED INHALATION RESEARCH, INC. (hereinafter AIR) and to a Joint Invention Agreement by and between M.I.T. and the PENNSYLVANIA STATE RESEARCH FOUNDATION (hereinafter PSRF). 

WHEREAS, AIR has clarified their business strategy and developed certain prototype products, and has determined that THERAPEUTIC PARTICLES will be their
principal product, and that most pharmaceuticals incorporated into such THERAPEUTIC PARTICLES will be HIGH COST THERAPEUTIC AGENTS; and 
 WHEREAS, there
are COMPARABLE THERAPEUTIC AGENTS (as later defined herein) on the market against which it is possible to determine the relative value of LICENSED PRODUCTS; and 

NOW, THEREFORE, the parties hereby agree to modify the License Agreement as follows: 

Delete paragraph 1.17 in its entirety and replace it with: 

1.17 “COMPARABLE THERAPEUTIC AGENT” shall mean a proprietary agent, explicitly not delivered via a PARTICLE, currently being prescribed according to
standard clinical practice to treat, manage, or diagnose a medical condition, which condition can now be treated, managed or diagnosed using THERAPEUTIC PARTICLES, and approved by M.I.T. according to the procedure in paragraph 5.6. 

Delete paragraphs 1.10(a) and (b) in their entirety and replace with: 

1.10(a) NET Sales of THERAPEUTIC PARTICLES shall be the difference between the price a third party pays for a dosing regimen of THERAPEUTIC PARTICLES
and the price a comparable third party would pay for a comparable dosing regimen of a COMPARABLE THERAPEUTIC AGENT which has not been incorporated into a PARTICLE. An example of the computation of the royalty owed by LICENSEE on NET SALES of
THERAPEUTIC PARTICLES under paragraph 4.1(e) is attached as Exhibit A. 
 1.10(b) NET SALES of ADMINISTRATION SYSTEMS which deliver THERAPEUTIC PARTICLES
shall be the difference between the price that a third party pays for a ADMINISTRATION SYSTEM which delivers THERAPEUTIC PARTICLES and the price that a comparable third party would pay for a comparable ADMINISTRATION SYSTEM which delivers a
COMPARABLE THERAPEUTIC AGENT without the use of PARTICLES. 
 Add the following sentences to the end of paragraphs 2.3(b) and 2.3(c). 

M.I.T. will provide such notice prior to the grant LICENSEE understands that such notice will not be triggered by the written request. 

 THIS EXHIBIT HAS BEEN REDACTED AND IS THE SUBJECT OF A CONFIDENTIAL TREATMENT
REQUEST. REDACTED MATERIAL IS MARKED WITH [* * *] AND HAS BEEN FILED SEPARATELY WITH THE SECURITIES AND EXCHANGE COMMISSION. 
  

 Delete paragraph 4.1(c)(v) and replace it with: 

License Maintenance Fee of [***] payable on January 1, 2003, January 1, 2004, January 1, 2005, January 1, 2006, and
January 1, 2007, provided, however, that License Maintenance Fees may be credited to Running Royalties due on NET SALES for the corresponding calendar year, if any. A License Maintenance Fee paid in excess of Running Royalties shall not be
creditable to Running Royalties for future years. 
 Add paragraph 4.1(c)(vi): 

License Maintenance Fee of [***] payable on January l, 2008, and on January 1 of each subsequent year, provided, however, that these License Maintenance
Fees may be credited to Running Royalties subsequently due on NET SALES for calendar year 2008, and for each subsequent year, if any. A License Maintenance Fee paid in excess of Running Royalties shall not be creditable to Running Royalties for
future years. 
 Delete paragraph 4.6 in its entirety. 

Delete paragraphs 5.2(b), (c) and (d) in their entirety and replace them with: 

5.2(b) accounting related to the special provisions of paragraph 1.10(a), including 

(i) identity of COMPARABLE THERAPEUTIC AGENTS, and their vendors. 

(ii) a brief explanation of why such agent is a COMPARABLE THERAPEUTIC AGENT, including the medical indication for such COMPARABLE THERAPEUTIC
AGENT and in what ways it is similar or identical to the therapeutic indication for THERAPEUTIC PARTICLES. 
 (iii) the price a comparable
third party would pay for a comparable dosing regimen of a COMPARABLE THERAPEUTIC AGENT, the identity of the comparable third party, a brief explanation of why it is a comparable third party, (example, both purchasers are HMO’s), the identity
of the dosing regimen, and a brief explanation of why the dosing regimen is comparable (example, both regimens are a one week supply of the drug, even though THERAPEUTIC PARTICLES are only taken once a day, and COMPARABLE THERAPEUTIC AGENTS are
taken twice a day). 
 (iv) calculation of loyalties due based on the difference between the price a third party pays for a dosing
regimen of THERAPEUTIC PARTICLES and the price a compatible third party would pay for a comparable dosing regimen of a COMPARABLE THERAPEUTIC AGENT which has not been incorporated into a PARTICLE. An example of the computation of the royalty owed by
LICENSEE on NET SALES of THERAPEUTIC PARTICLES under paragraph 4.1(e) is attached as Exhibit A. 
 5.2 (e) accounting relaxed to the
special provisions of paragraph 1.10 (b), including 
 (i) identity of COMPARABLE THERAPEUTIC AGENTS being delivered via ADMINISTRATION
SYSTEMS, and the vendors of such COMPARABLE THERAPEUTIC AGENTS delivered via ADMINISTRATION SYSTEMS. 
 (ii) a brief explanation of why such
agent is a COMPARABLE THERAPEUTIC AGENT, including the medical indication for such COMPARABLE THERAPEUTIC AGENT delivered via an ADMINISTRATION SYSTEM, and in what ways it is similar or identical to the therapeutic indication for an ADMINISTRATION
SYSTEM delivering THERAPEUTIC PARTICLES. 

 THIS EXHIBIT HAS BEEN REDACTED AND IS THE SUBJECT OF A CONFIDENTIAL TREATMENT
REQUEST. REDACTED MATERIAL IS MARKED WITH [* * *] AND HAS BEEN FILED SEPARATELY WITH THE SECURITIES AND EXCHANGE COMMISSION. 
  

 (iii) the prices paid by comparable purchasers for the two ADMINISTRATION SYSTEMS, one
delivering COMPARABLE THERAPEUTIC AGENTS, the other delivering THERAPEUTIC PARTICLES, and a brief explanation of why such purchasers are comparable (example, both purchasers are HMO’s), the dosing regimen of the two ADMINISTRATION SYSTEMS, and
a brief explanation of why the dosing regimens are comparable (example, both ADMINISTRATION SYSTEMS deliver a one week supply of the drug). 

(iv) calculation of royalties due based on the difference between the price of the two ADMINISTRATION SYSTEMS. 

Add paragraphs 5.6. 
 5.6 Within Thirty (30) days of
receipt of the information pertinent to a royalty accounting described in paragraph 5.2, including, but not limited to paragraph 5.2(b) and 5.2(c) above, and also payment due per paragraph 5.3, M.I.T. shall notify LICENSEE in writing, of whether or
not M.I.T. approves of the basis of the royalty calculation and resulting payment, such approval not to be unreasonably withheld. Failure of M.I.T. to so notify LICENSEE within Thirty (30) days of receipt of both the payment due per paragraph
5.3, and the information described in paragraph 5.2, shall be deemed to constitute such approval. If M.I.T. does not approve of the basis of the royalty calculation, the M.I.T. shall so notify LICENSEE in writing, and the parties shall meet in good
faith to resolve the matter, and either party may invoke the dispute resolution mechanisms of paragraph 12. 
 Modify the fourth sentence of paragraph 6.1
by adding “David Brook,” after “Patrea Pabst.” 
 Modify paragraph 14 so that the address for legal notice of AIR is: 

c/o David A. Edwards, President 
 Advanced Inhalation Research,
Inc. 
 840 Memorial Drive 
 Cambridge, MA 02142 

 

									
	Agreed to for M.I.T. by	 		 	Agreed to for A.I.R. by
			
	MASSACHUSETTS INSTITUTE OF TECHNOLOGY	 		 	ADVANCED INHALATION RESEARCH
					
	By:	 	 /s/ Lori Pressman
	 		 	By:	 	 /s/ David Edwards

	Name:	 	 Lori Pressman
	 		 	Name:	 	 David Edwards

	Title:	 	 Assistant Director, Technology Licensing Office
	 		 	Title:	 	 President

	Date:	 	 January 27, 1999
	 		 	Date:	 	 January 27, 1999

 THIS EXHIBIT HAS BEEN REDACTED AND IS THE SUBJECT OF A CONFIDENTIAL TREATMENT
REQUEST. REDACTED MATERIAL IS MARKED WITH [* * *] AND HAS BEEN FILED SEPARATELY WITH THE SECURITIES AND EXCHANGE COMMISSION. 
  

 EXHIBIT A 

AIR/MIT License Agreement 

Therapeutic Particle Royalty Computation* 
  

																	
	 	  	COMPARABLE
THERAPEUTIC AGENT
unit Dose Sale Price1	 	 	AIR unit Dose
Sale Price2	 	 	Difference	 	 	MIT Royalty
([***]	 
					
	 • GH
	  	 	[***	] 	 	 	[***	] 	 	 	[***	] 	 	 	[***	] 
					
	 • Insulin
	  	 	[***	] 	 	 	[***	] 	 	 	[***	] 	 	 	[***	] 
					
	 • Albuterol
	  	 	[***	] 	 	 	[***	] 	 	 	[***	] 	 	 	[***	] 
					
	 • Estradiol
	  	 	[***	] 	 	 	[***	] 	 	 	[***	] 	 	 	[***	] 
					
	 • GLIP (est)
	  	 	[***	] 	 	 	[***	] 	 	 	[***	] 	 	 	[***	] 
					
	 • CP (est)
	  	 	[***	] 	 	 	[***	] 	 	 	[***	] 	 	 	[***	] 
					
	 • Fluticasone
	  	 	[***	] 	 	 	[***	] 	 	 	[***	] 	 	 	[***	] 
					
	 • Salmeterol
	  	 	[***	] 	 	 	[***	] 	 	 	[***	] 	 	 	[***	] 

  

	*	Based on current estimates of product prices (subject to change based on market conditions) 

 

	1 	Equivalent daily therapy with existing marketed competitive formulation. GH based on injectable, insulin or inhaled insulin (3/day), albuterol on inhaled albuterol (2/day), estradiol on oral estradiol (1/day), GLIP on
oral insulin drugs (3/day), CP on inhaled corcosteroid (2/day), fluticasone on inhaled fluticasone (2/day), salmeterol on inhaled salmeterol (2/day). 

	2 	Unit dose refers to single-day therapy.

Source: [{"source": "alea-institute/alea-institute/kl3m-data-edgar-agreements/train-00235-of-00352.parquet"}, [{"source": "alea-institute/alea-institute/kl3m-data-edgar-agreements/train-00235-of-00352.parquet"}]]